Core binding factor (CBF) positive AML (CBFpos AML) represents 5–8% of all AMLs and is defined by the presence of a t(8;21)(q22;q22) and the associated RUNX1–RUNX1T1 fusion gene, or an inv(16)(p13.1q22)/t(16;16)(p13.1;q22) with the resulting CBFB–MYH11 fusion gene. Here, CEBPZ is linked to acute myeloid leukemia.